Log in

NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News

$8.96
+0.60 (+7.18 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.36
Now: $8.96
$8.96
50-Day Range
$6.51
MA: $8.26
$9.67
52-Week Range
$4.62
Now: $8.96
$10.38
Volume302,969 shs
Average Volume460,219 shs
Market Capitalization$440.29 million
P/E RatioN/A
Dividend YieldN/A
Beta0.37
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Read More
Unity Biotechnology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees94
Market Cap$440.29 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have increased by 66.2% and is now trading at $8.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) released its earnings results on Thursday, May, 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.03. View Unity Biotechnology's earnings history.

What price target have analysts set for UBX?

3 analysts have issued 1-year price objectives for Unity Biotechnology's shares. Their forecasts range from $13.00 to $33.00. On average, they anticipate Unity Biotechnology's stock price to reach $22.00 in the next year. This suggests a possible upside of 145.5% from the stock's current price. View analysts' price targets for Unity Biotechnology.

Has Unity Biotechnology been receiving favorable news coverage?

Media headlines about UBX stock have been trending negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Unity Biotechnology earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View the latest news about Unity Biotechnology.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,670,000 shares, an increase of 8.1% from the June 15th total of 4,320,000 shares. Based on an average trading volume of 288,500 shares, the days-to-cover ratio is currently 16.2 days. Currently, 18.6% of the company's shares are short sold. View Unity Biotechnology's Current Options Chain.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
  • Dr. Anirvan Ghosh, Director & CEO (Age 56)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $8.96.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $440.29 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.